Authors
Latest:
AUPN 2022 Women Leaders in NeurologyLaurie Gutmann, MD; Gauri Pawar, MD; and Claire Henchcliffe, MD, discuss their own paths in medicine and observations of other women leaders. [WATCH TIME: 1 hour, 51 minutes]
Latest:
PPD/TFS Fostering Global Awareness in Rare DisordersRare Disease Day raises awareness for rare disorders, highlighting challenges, improving detection, and fostering collaboration for treatment advancements.
Latest:
Roundtable: The Future of Stereotactic and Functional NeurosurgeryTwo experts at Jefferson Health discuss several topics related to advances in neurosurgery, technology, and the future of minimally invasive procedures.
Latest:
Trichloroethylene Exposure and Usage, Environmental Associations in Parkinson Disease: Samuel M. Goldman, MD, MPHThe clinical professor in the department of neurology at the University of California, San Francisco, emphasized the need to restrict trichloroethylene availability and the challenges in studying environmental factors associated with Parkinson disease. [WATCH TIME: 4 minutes]
Latest:
AUPN Leadership Minute Episode 31: Recruitment and Retention of FacultyEpisode 31 of the AUPN Leadership Minute features Donald S. Higgins, Jr., MD, of the VHA and Albany Medical College; and Adam Newsom, of Merritt Hawkins. [WATCH TIME: 5 minutes]
Latest:
Therapeutic Potential of Transcranial Direct Current Stimulation in Primary Progressive Aphasia: Leigh Charvet, PhDThe professor of neurology at the NYU Grossman School of Medicine provided commentary on a study that demonstrated the benefits of using tDCS along with sleep language training to promote naming in primary progressive aphasia. [WATCH TIME: 5 minutes]
Latest:
The State of Coma Care: A Call for ActionOur moon shot to curing coma will take everyone. We all need to work together toward the grand challenge of awakening hope.
Latest:
Overviewing Phase 2 SYNAPSE-SMA Trial of NMD670 for Spinal Muscular Atrophy: Jorge Quiroz, MD, MBAThe chief medical officer of NMD Pharma provided perspective on a newly launched phase 2 study assessing NMD670, a first-in-class neuromuscular transmission enhancer, in patients with spinal muscular atrophy type 3. [WATCH TIME: 5 minutes]
Latest:
Understanding Patient Characteristics of Phase 3 APOLLOE4 Trial of ALZ-801 in Alzheimer Disease: John Hey, PhDThe chief scientific officer at Alzheon provided insight on the preliminary imaging findings of patients enrolled in the phase 3 APOLLOE4 study assessing ALZ-801 as a potential treatment for Alzheimer disease. [WATCH TIME: 3 minutes]
Latest:
Clinical Implications on the Influence of the Microbiome on Migraine Regulation: Blanca Marquez de Prado, PhDThe research project manager of the headache program at the Children's Hospital of Philadelphia discussed data that suggest that an unhealthy and imbalanced microbiome may exacerbate the frequency, severity, and duration of migraines. [WATCH TIME: 4 minutes]
Latest:
The Role of Nurse Practitioners in Multidisciplinary Stroke Care: Johanna L. Watkinson, APNThe acute care nurse practitioner at Overlook Medical Center spoke to the importance of having a multidisciplinary team when treating patients with stroke and the gaps that advanced practice providers can help fill.
Latest:
An Overview of Therapeutic Options for Amyotrophic Lateral SclerosisWith an anticipated life expectancy of 3 years from the time of symptom onset, an effective treatment strategy is essential in ALS—and recent therapeutic progress has built a foundation of hope for the community.
Latest:
Pediatric Sleep Disorders: Assessment and TreatmentThe long-term consequences of untreated—and prevalent—sleep disorders in children and adolescents point to a need for a focus on this field of care.
Latest:
In Memoriam: A Loving Tribute to June HalperNeurologyLive joins the CMSC in mourning the loss of founder and CEO,June Halper, MSN, APC-C, MSCN, FAAN.
Latest:
Retrospectively Exploring De-Escalation of Multiple Sclerosis Medication: Carolyn H. Goldschmidt, DOThe neurologist at NorthShore University Health System in Chicago discussed a retrospective study on patients with multiple sclerosis who switched from high or moderate efficacy disease-modifying therapies to lower efficacy ones. [WATCH TIME: 5 minutes]
Latest:
Sleeping Around the Podcast × NeurologyLive: Erenumab, Migraine, and SleepSleeping Around the Podcast × NeurologyLive brings you a clinical overview of the use of erenumab, an FDA-approved medication for migraine, and the interactions between CGRP and orexin.
Latest:
Treatment Options and Outcomes of Cervical Artery Dissection in Adults: Eytan Raz, MD, PhDThe neurointerventional radiologist at NYU Langone provided clarity on the individualized treatment options for cervical artery dissection following a scientific statement paper from the American Heart Association. [WATCH TIME: 7 minutes]
Latest:
American Heart Association Statement Stresses Need for Comprehensive Post-Stroke CareThe collaborative newly published statement stressed the need to address gaps in care that may lead to high risk of stroke recurrence.
Latest:
Expanding the Migraine Treatment Protocol Beyond CGRPs: Emad Estemalik, MDThe director of the headache section at Cleveland Clinic detailed some of the emerging nonpharmacological preventive methods for migraine, as well as where research is headed following the explosion of CGRP-targeting therapies. [WATCH TIME: 6 minutes]
Latest:
Mechanistic Potential of Synapse-Targeted Agent ALX-001 for Alzheimer Disease: Adam Mecca, MD, PhDThe associate director of the Alzheimer’s Disease Research Unit at the Yale School of Medicine discussed the mechanism of action of ALX-001, a highly selective agent in development for neurodegenerative diseases. [WATCH TIME: 5 minutes]
Latest:
Role of Sleep Chronotype, Circadian Rhythm in Neurocognitive Health: Ashley Curtis, PhDThe assistant professor at the University of South Florida provided perspective on the influence of circadian rhythm in neurocognitive health and the possibilities of screening for circadian rhythm issues for large-scale clinical trials. [WATCH TIME: 4 minutes]
Latest:
Early Intervention and Disease Prevention With a Novel Epigenome Approach: Boris Kantor, PhDThe associate research professor of neurobiology at Duke University discussed an innovative epigenome editing approach that shows promising prospects for patient improvement, disease prevention, and potential use in Alzheimer disease prophylactic work. [WATCH TIME: 3 minutes]
Latest:
Pridopidine’s Impact on ALS, Assessing Results From HEALEY ALS Platform Trial: Melanie Leitner, PhDThe consultant and founder of Accelerating NeuroVentures talked about the pridopidine arm from the HEALEY ALS Platform trial, which showed significant benefits in speech measures. [WATCH TIME: 5 minutes]
Latest:
AUPN Leadership Minute Episode 29: Transitioning From Chair to VP and DeanEpisode 29 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Allison Brashear MD, MBA, of University at Buffalo. [WATCH TIME: 5 minutes]
Latest:
Additive Potential of BTK Inhibitors in Multiple Sclerosis Treatment Paradigm: Diana Gallagher, MDThe head of Biogen’s MS and Immunology Department Unit detailed the potential of combination approaches to treat MS, including the reasons for diroximel fumarate in the newly initiated phase 2 FUSION study. [WATCH TIME: 3 minutes]
Latest:
Highlights of ISC 2024, Trials and Future Innovations for Stroke Care: Tudor Jovin, MD; Lauren Sansing, MD, MS, FAHAThe medical director of the Cooper Neurological Institute and the professor of neurology at Yale University School of Medicine shared a few highlights from research presented at ISC 2024. [WATCH TIME: 7 minutes]
Latest:
Cure Rare Disease Identifies Toxicity Responsible for DMD Gene Therapy DeathCaution is warranted for older patients with Duchenne muscular dystrophy who are receiving gene therapy, according to details of a patient death in a single patient trial.
Latest:
Therapeutic Approaches to Fatigue in Multiple Sclerosis: Anna Kratz, PhDDiscussing cognitive behavioral therapy for patients with MS, the associate professor of Physical Medicine and Rehabilitation and research nonclinical psychologist at the University of Michigan Medicine mentioned different therapeutic options that can benefit this patient population. [WATCH TIME: 3 minutes]
